Mike Kratky
Stock Analyst at Leerink Partners
(3.43)
# 852
Out of 4,842 analysts
27
Total ratings
47.37%
Success rate
33.27%
Average return
Main Sectors:
Stocks Rated by Mike Kratky
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BBNX Beta Bionics | Initiates: Outperform | $28 | $14.45 | +93.77% | 1 | Feb 24, 2025 | |
| TXG 10x Genomics | Downgrades: Market Perform | $25 → $12 | $8.86 | +35.44% | 2 | Feb 13, 2025 | |
| DXCM DexCom | Maintains: Outperform | $90 → $87 | $86.98 | +0.02% | 2 | Oct 25, 2024 | |
| INSP Inspire Medical Systems | Maintains: Market Perform | $167 → $197 | $140.28 | +40.43% | 2 | Sep 10, 2024 | |
| PEN Penumbra | Initiates: Outperform | $263 | $264.29 | -0.49% | 1 | Sep 3, 2024 | |
| TNDM Tandem Diabetes Care | Upgrades: Outperform | $34 → $45 | $21.15 | +112.77% | 2 | Apr 25, 2024 | |
| NPCE NeuroPace | Initiates: Outperform | $22 | $12.46 | +76.57% | 1 | Jan 30, 2024 | |
| PODD Insulet | Initiates: Outperform | $184 | $323.33 | -43.09% | 1 | Oct 16, 2023 | |
| VCEL Vericel | Initiates: Outperform | $42 | $42.15 | -0.36% | 1 | Oct 16, 2023 | |
| ISRG Intuitive Surgical | Initiates: Outperform | $342 | $552.41 | -38.09% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $75 | $76.66 | -2.17% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $37 | $58.64 | -36.90% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $9 | $10.96 | -17.88% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $325 → $50 | $3.00 | +1,566.67% | 2 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $33 → $45 | $1.35 | +3,233.33% | 2 | Jan 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $145 → $315 | $270.87 | +16.29% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $26 → $31 | $28.80 | +7.64% | 2 | Dec 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $14 | $14.09 | -0.64% | 1 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $40 | $13.50 | +196.30% | 1 | Aug 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $49 → $48 | $0.97 | +4,833.70% | 1 | Aug 11, 2022 |
Beta Bionics
Feb 24, 2025
Initiates: Outperform
Price Target: $28
Current: $14.45
Upside: +93.77%
10x Genomics
Feb 13, 2025
Downgrades: Market Perform
Price Target: $25 → $12
Current: $8.86
Upside: +35.44%
DexCom
Oct 25, 2024
Maintains: Outperform
Price Target: $90 → $87
Current: $86.98
Upside: +0.02%
Inspire Medical Systems
Sep 10, 2024
Maintains: Market Perform
Price Target: $167 → $197
Current: $140.28
Upside: +40.43%
Penumbra
Sep 3, 2024
Initiates: Outperform
Price Target: $263
Current: $264.29
Upside: -0.49%
Tandem Diabetes Care
Apr 25, 2024
Upgrades: Outperform
Price Target: $34 → $45
Current: $21.15
Upside: +112.77%
NeuroPace
Jan 30, 2024
Initiates: Outperform
Price Target: $22
Current: $12.46
Upside: +76.57%
Insulet
Oct 16, 2023
Initiates: Outperform
Price Target: $184
Current: $323.33
Upside: -43.09%
Vericel
Oct 16, 2023
Initiates: Outperform
Price Target: $42
Current: $42.15
Upside: -0.36%
Intuitive Surgical
Oct 16, 2023
Initiates: Outperform
Price Target: $342
Current: $552.41
Upside: -38.09%
Oct 16, 2023
Initiates: Market Perform
Price Target: $75
Current: $76.66
Upside: -2.17%
Oct 16, 2023
Initiates: Outperform
Price Target: $37
Current: $58.64
Upside: -36.90%
Oct 16, 2023
Initiates: Outperform
Price Target: $9
Current: $10.96
Upside: -17.88%
Aug 15, 2023
Downgrades: Market Perform
Price Target: $325 → $50
Current: $3.00
Upside: +1,566.67%
Jan 24, 2023
Maintains: Outperform
Price Target: $33 → $45
Current: $1.35
Upside: +3,233.33%
Dec 20, 2022
Maintains: Outperform
Price Target: $145 → $315
Current: $270.87
Upside: +16.29%
Dec 15, 2022
Maintains: Market Perform
Price Target: $26 → $31
Current: $28.80
Upside: +7.64%
Nov 4, 2022
Maintains: Outperform
Price Target: $12 → $14
Current: $14.09
Upside: -0.64%
Aug 15, 2022
Maintains: Outperform
Price Target: $32 → $40
Current: $13.50
Upside: +196.30%
Aug 11, 2022
Maintains: Outperform
Price Target: $49 → $48
Current: $0.97
Upside: +4,833.70%